Patents for A61P 35 - Antineoplastic agents (221,099)
06/2009
06/25/2009WO2009078756A1 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
06/25/2009WO2009078755A1 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
06/25/2009WO2009078754A1 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
06/25/2009WO2009078474A1 An agent for reducing a side effect of an anticancer drug
06/25/2009WO2009078423A1 Fused tricyclic compound having aldose reductase inhibitory activity
06/25/2009WO2009078035A1 Extract of piper betel leaves for the treatment of human malignancies by inducing oxidative stress
06/25/2009WO2009077908A1 Colloidal particle comprising multivalent cyclic anions
06/25/2009WO2009077741A2 3-substituted-4-0x0-3, 4-dihydro-imidazo- [5, 1-d] [1,2,3,5] -tetrazine-8-carboxylic acid amides as anticancer agents
06/25/2009WO2009077586A2 Methods and compositions for the preparation and use of toxin conjugates
06/25/2009WO2009077448A1 Kinesin inhibitors as cancer therapeutics
06/25/2009WO2009077401A1 Antitumoral compounds
06/25/2009WO2009077186A1 Nonsteroidal progesterone receptor modulators
06/25/2009WO2009076824A1 Genes encoding major capsid protein l1 of human papilloma virus's
06/25/2009WO2009076761A1 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
06/25/2009WO2009060292A3 Smac mimetic compounds as apoptosis inducers
06/25/2009WO2009058729A3 Thiazole carboxamide derivatives and their to treat cancer
06/25/2009WO2009056692A3 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
06/25/2009WO2009053644A3 Use of lanthanide-based nanoparticles as radiosensitizing agents
06/25/2009WO2009053038A3 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
06/25/2009WO2009052200A3 Human adam-10 inhibitors
06/25/2009WO2009049961A3 New no-donor aspirin derivatives
06/25/2009WO2009048541A3 Compounds and methods for use in treating neoplasia and cancer
06/25/2009WO2009046875A3 Combination of splenopentin and thymopentin and the use thereof in medicine
06/25/2009WO2009046863A3 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent
06/25/2009WO2009046842A3 Thiazol derivatives for treating cancer
06/25/2009WO2009046123A3 Nlrr-1 antagonists and uses thereof
06/25/2009WO2009043051A3 Cd23 binding molecules and methods of use thereof
06/25/2009WO2009040046A3 Use of stresscopin-related peptide as a therapeutic agent
06/25/2009WO2009040021A3 Use of a peptide as a therapeutic agent
06/25/2009WO2009034547A3 New 4-substituted derivatives of pyrazolo[3,4-d pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof
06/25/2009WO2009033746A3 Use of a peptide as a therapeutic agent
06/25/2009WO2009027994A4 NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3β-OL
06/25/2009WO2009025760A3 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
06/25/2009WO2009017833A3 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
06/25/2009WO2008103431A3 Dnai - liposomes
06/25/2009WO2008076278A4 Methods of cancer treatment with igf1r inhibitors
06/25/2009WO2008046084A3 Spiroheterocyclic compounds and their uses as therapeutic agents
06/25/2009US20090163600 Anti-Inflammatory Agent and Cancer-Preventive Agent Comprising Canolol or Prodrug Thereof and Pharmaceutical, Cosmetic and Food Comprising the Same
06/25/2009US20090163591 Use of sugar phosphates, sugar phosphate analogs, amino acids and/or amino acid analogs for modulating the glucolysis-enzyme complex, the malate asparate shuttle and/or the transaminases
06/25/2009US20090163587 Ester prodrugs of prostratin and related phorbol compounds
06/25/2009US20090163581 Pharmaceutical Products for Treating Neoplastic Disease and Inflammation
06/25/2009US20090163580 Anti-aging composition containing resveratrol and method of administration
06/25/2009US20090163577 METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS
06/25/2009US20090163556 Glycinamide derivatives as raf-kinase inhbitors
06/25/2009US20090163555 Isolated optically active stereoisomers are useful for enhancing an immuneresponse, for treating autoimmune diseases and asantitumor agents, bacteriacides, fungicides or viricides; one pot synthesis of1-(3-a3S,5R-1-(3-amino-5-carboxy-2-oxopyrrolidin-3-ylmethyl)pyridinium bromide hydrobromide
06/25/2009US20090163552 Carboxyl- or hydroxyl-substituted benzimidazole derivatives
06/25/2009US20090163538 Tetrahydropyridothiophenes For Use In The Treatment Of Cancer
06/25/2009US20090163533 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases
06/25/2009US20090163525 Substituted quinazolines with anti-cancer activity
06/25/2009US20090163524 Novel Protein Kinase B Inhibitors - 060
06/25/2009US20090163522 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same
06/25/2009US20090163515 Compounds Which Bind to the Active Site of Protein Kinase Enzymes
06/25/2009US20090163507 Synthesis of naturally occuring ecteinascidins and related compounds
06/25/2009US20090163505 Amino-heteroaryl-containing prokineticin 1 receptor antagonists
06/25/2009US20090163503 Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
06/25/2009US20090163501 Aurora kinase modulators and method of use
06/25/2009US20090163494 Protein kinase inhibitors
06/25/2009US20090163493 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor
06/25/2009US20090163489 Inhibitors of PI3 kinase
06/25/2009US20090163488 Fused heterocycle derivatives and use thereof
06/25/2009US20090163481 Ppar-delta ligands and methods of their use
06/25/2009US20090163479 Use of taurolidine to treat tumors
06/25/2009US20090163477 Phthalazinone derivatives
06/25/2009US20090163469 Organic Compounds
06/25/2009US20090163468 Fused Bicyclic mTor Inhibitors
06/25/2009US20090163467 New compounds
06/25/2009US20090163465 Pyrimidines as PLK inhibitors
06/25/2009US20090163463 Organic Compounds
06/25/2009US20090163453 Prevention and Treatment of Gastrointestinal and Bladder Disorders Associated with Chemotherapy or Radiation Therapy Using Active Vitamin D Compounds
06/25/2009US20090163450 Combinations comprising a prostaglandin and uses thereof
06/25/2009US20090163446 Diazonamide analogs with improved solubility
06/25/2009US20090163442 Treatment of cancer with 2-deoxygalactose
06/25/2009US20090163438 Gankyrin
06/25/2009US20090163426 Prostate specific antigen; immobilization; antiproliferative agents; drug delivery; contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA); useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs
06/25/2009US20090163414 In-vitro method for screening accessible biological markers in pathological tissues
06/25/2009US20090163411 Long acting vegf inhibitors and methods of use
06/25/2009US20090163407 Compositions and methods for altering wnt autocrine signaling
06/25/2009US20090163406 Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
06/25/2009US20090162454 Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor
06/25/2009US20090162440 Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof
06/25/2009US20090162425 Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
06/25/2009US20090162382 Optimized ca9 antibodies and methods of using the same
06/25/2009US20090162380 Multispecific binding molecules comprising connecting peptides
06/25/2009US20090162372 Fibronectin ed-b antibodies, conjugates thereof, and methods of use
06/25/2009US20090162367 Nucleotide and protein sequences of Nogo genes and methods based thereon
06/25/2009US20090162364 Apo-2 ligand
06/25/2009US20090162354 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
06/25/2009US20090162338 Inhibiting metastasis of cancer cells by administering a phosphatidyl inositol 3-kinase inhibitor such as Wortmannin or LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)
06/25/2009US20090162333 Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
06/25/2009US20090162313 High-Molecular Weight Conjugate of Podophyllotoxins
06/25/2009US20090162299 Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
06/25/2009US20090162289 A tetrapyrollic photosensitizer compound with one pendant CH2CH2CON(CH2CON(CH2COOH)2)2 or N(CH2COOH)2 group, being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide; water soluble photosensitizing and imaging compounds; hyperproliferative tissue
06/25/2009US20090162284 Anti-igf-i receptor antibody
06/25/2009US20090162281 Radionuclide labeling of Vitamin B12 and Co-enzymes thereof
06/25/2009DE102007061963A1 Pyridazinonderivate Pyridazinone derivatives
06/25/2009CA2709749A1 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]-tetrazine-8-carboxylic acid amides and their use
06/25/2009CA2709463A1 Trail variants for treating cancer
06/25/2009CA2709268A1 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
06/25/2009CA2709267A1 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
06/25/2009CA2709266A1 Drug delivery system for administration of poorly water soluble pharmaceutically active substances